This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Elevating the Quality of Care in Ulcerative Colitis: Using Patient Cases and Expert Insights to Improve Real-World Practice

Elevating the Quality of Care in Ulcerative Colitis: Using Patient Cases and Expert Insights to Improve Real-World Practice

Format

Roundtable

Time to Complete

1.50 hours

Released

October 31, 2017

Expires

October 30, 2018
Add to Queue


Maximum Credits

1.50 / AMA PRA Category 1 CreditsTM
1.83 / CNE Contact Hours (1.83 of which is eligible for pharmacology credit)
1.50 / ABIM MOC Part II Points

An important note about ABIM MOC Part II points
Successful completion of this CME activity enables eligible participants to earn up to 1.50 ABIM-Part II Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. To claim MOC points, follow these easy steps:

Step 1: After completing this activity, select "AMA PRA Category 1 Credit(s)TM/ABIM MOC point(s)" on the Claim Credit page.

Step 2: Enter your ABIM ID number and day and month of birth in the pop-up box that will appear. Be sure to check the box to attest that myCME may send your MOC points to ABIM. myCME will store your data, so if you have submitted MOC points through myCME for other activities, you will need only to attest that myCME may send the information.

Step 3: Click the blue "View Certificate in Profile" button. Your MOC points will be sent to your ABIM account within 24 hours.

Accredited Provider



Provided by Boston University School of Medicine

Endorsed By



Endorsed by the AGA Institute.

Commercial Supporter

This activity is supported by independent educational grants from Abbvie Inc., and Takeda Pharmaceuticals U.S.A Inc.

Program Description

The objective of this interactive on-demand, enduring Internet activity is to provide gastroenterology clinicians and others with the latest data regarding evolving treatment goals in ulcerative colitis (UC), adoption of an individualized treatment approach to the selection, initiation, and tailoring of disease-modifying therapies for achieving and sustaining remission of UC, and elucidation of the key clinical findings and protocols established in decision support tools published for gastroenterology professionals who manage/treat patients with UC.

Utilizing an expert faculty team and featuring video vignettes of actual patients, the objective of this web-based activity is to provide clinicians with a better understanding of the “hot topics” in UC arising from current clinical and research data, and pertinent guideline updates, specifically the recent collection of clinical decision support tools designed specifically for IBD care pathways by the American Gastroenterological Association (AGA). For each clinical scenario, the program moderator will invite the faculty to make a short didactic case presentation from the “hot seat.” During the case presentation, faculty will challenge the audience to make treatment decisions, focusing on patients with unmet needs in UC. At the conclusion of each case presentation, the faculty will participate in a brief roundtable discussion moderated by the Activity Chair.

Intended Audience

This activity is intended for gastroenterologists, primary care physicians, NP/PAs, nurses, and other applicable clinicians who manage/treat patients with UC.

Educational Objectives

Upon completion of these activities, participants should be better able to:

  • Identify patients with moderate-to-severe ulcerative colitis (UC) who are at high risk for adverse outcomes including surgery and select appropriate treatment for these patients
  • Describe reasons for non-response to UC therapy and be able to adjust treatment regimens using evidence-based algorithms and data for various treatment options to help patients attain remission
  • Discuss the safety, efficacy, place in therapy, and impact on practice of biologic agents and small molecules that are currently in clinical trials for the treatment of UC
  • Analyze real-world data to improve the quality of care provided for UC in clinical practice, scrutinize the safety and efficacy of various treatment options, and review data to find patterns that can provide insights into clinical challenges in UC

Conflict Of Interest Disclosure Policy

Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Faculty

Francis A. Farraye, MD, MSc
Course Director
Clinical Director in the Section of Gastroenterology
Director of the Inflammatory Bowel Disease Center
Boston Medical Center
Professor of Medicine
Boston University School of Medicine
Boston, MA

Dr. Farraye is a consultant for AbbVie, Braintree, Celgene, Ferring, Janssen, Merck, Pfizer, Puma, and Takeda; receives grant/research support from Prometheus; is a stockholder of Cellceutix; and is a Data Safety Management Board member for Mesoblast and Protagonist.

Adam Cheifetz, MD, FACG
Director of the Inflammatory Bowel Disease Center
Beth Israel Deaconess Medical Center
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Dr. Cheifetz is a consultant for AbbVie, Janssen, Takeda, Pfizer, Miraca, and Samsung.

James Lewis, MD
Associate Director of the Inflammatory Bowel Disease Program
Director of the Gastroenterology and Hepatology Clinical Research Program
Professor of Medicine and Epidemiology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

Dr. Lewis receives grant support from AbbVie, Takeda, and Janssen; is a consultant for Janssen, Johnson and Johnson, Lilly, and Merck; receives non-financial research support from AbbVie; and is a Data Safety Management Board member for UCB, Pfizer, and Gilead.

Accredited Provider Disclosure

Patti-Ann Collins, Lead Nurse Planner for Boston University School of Medicine’s Office of Continuing Medical Education, has no relevant financial relationships to disclose.

Michael Burk, Senior Program Manager, Dana Frazier, Program Manager – Grant Funding, and Joanna Krause, Grants Manager of Boston University School of Medicine, Continuing Medical Education have no relevant financial relationships to disclose.

Beth-Ann Norton, Nursing Course Advisor for Boston University School of Medicine’s Office of Continuing Medical Education, has no relevant financial relationships to disclose.

Laura Stinson, consultant medical editor for Boston University School of Medicine’s Office of Continuing Medical Education, has no relevant financial relationships to disclose.

Sharmeel Wasan, MD, independent reviewer for Boston University School of Medicine’s Office of Continuing Medical Education, has no relevant financial relationships to disclose.

Planning Committee

Bret Lashner, MD
Co-Course Director
Director, Center for Inflammatory Bowel Disease
Department of Gastroenterology and Hepatology
Professor of Medicine
Cleveland Clinic
Cleveland, OH

Dr. Lashner has no relevant financial relationships to disclose.

Credit

1.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

Boston University School of Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.83

Type

CNE Contact Hour(s)

Accreditation Statement

Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation Statement

CNE Contact Hours: 1.83, all of which is eligible for pharmacology credit.

Credit

1.50

Type

AMA PRA Category 1 Credit(s)TM /ABIM MOC point(s)

Accreditation Statement

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education and the American Board of Internal Medicine's (ABIM) to provide continuing medical education for physicians.

Designation Statement

Boston University School of Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)TM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Part II
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 ABIM-Part II Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Unlabeled Use

The faculty members discuss the unlabeled/investigational use of 6-mercaptopurine (6MP), methotrexate, and tofactinib as treatment for ulcerative colitis.

Disclaimer

THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For any CME, CNE or ABIM MOC Part II accreditation questions please email the BUSM CME office at cme@bu.edu.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue